Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | Batch number no | — |
Anterior uveitis; Redness in his right eye; Pain in his right eye; Conjunctival hyperemia; Acute bacterial conjunctivitis; Photophobia; Blurry vision; Episcleritis; Ocular pain; This literature report (initial receipt 10-Mar-2026) concerns an adult male patient diagnosed with influenza disease. Patient with no known systemic or ocular health conditions received Afluria Trivalent (IIV3) influenza vaccine (lot number not reported - to be requested upon follow up), an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. No relevant medical or surgical history. Ocular history was unremarkable except for high myopia. Three days post-vaccination (Day 3), he experienced redness and pain in his right eye (OD), and given the persistence of symptoms, the patient sought medical attention from a non-ophthalmology physician at an Clinic on Day 5. Ocular examination revealed conjunctival hyperemia with no other significant findings noted. He was diagnosed with acute bacterial conjunctivitis with prescription of topical ciprofloxacin and olopatadine. On Day 6, his ocular pain worsened with the development of photophobia and blurry vision. Therefore, the patient visited an Emergency Department (ED) where he was examined by an ophthalmologist. His best-corrected visual acuity (BCVA) was 20/25 in both eyes (OU). The intraocular pressure (IOP) was 10 mmHg OD and 13 mmHg in his left eye (OS). No flare or cells were observed in the anterior chamber (AC) OU, and the conjunctival injection OD was significantly blanched with 2.5% phenylephrine eyedrop. The findings were in line with the diagnosis of episcleritis and oral indomethacin 50 mg, three times daily, was prescribed. Four days following the Nonsteroidal Anti-Inflammatory Drugs (NSAID) treatment (Day 10), there was a mild decrease in the ocular pain with persistent photophobia OD. Therefore, the patient revisited the ED to follow up with ophthalmology. Best Corrected Visual Acuity (BCVA) was 20/20 OU and slit lamp examination revealed fine keratic precipitates (KPs) with 3+ AC cells and flare and posterior synechia OD. IOP was 8 mmHg OD and 14 mmHg OS. Fundus examination OU revealed tigroid appearance, tilted optic disc with peripapillary atrophy. Moreover, no lesions were observed on the macula, optic nerve or retinal vessels OU. Peripheral myopic chorioretinal degeneration with pigmentation was noted inferiorly and temporally OU. Spectral-domain optical coherence tomography (SD-OCT) showed partial posterior vitreous detachment, myopic foveal contour with no macular edema OU. On the patient's visit to the Uveitis Service on Day 20, symptoms had markedly improved with decreased photophobia. Slit lamp examination was unremarkable in OS and revealed 1+ AC cells and flare with no KPs or posterior synechia OD. Posterior segment evaluation demonstrated no evidence of inflammation. Fundus fluorescein angiography (FFA) was performed and showed clear view with no evident macular, perivascular or optic nerve leakage OU. Peripheral staining corresponding to the myopic chorioretinal degeneration was noted inferiorly and temporally. The patient was reassured that the inflammation is resolving with a recommendation of slow tapering of topical steroids over 12 weeks and monitoring of any signs of deterioration such as pain, photophobia, blurry vision or floaters. A further evaluation with a rheumatologist confirmed erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are within normal value. There is no evidence of systemic involvement related to HLA-B27 positivity. By week four, the patient demonstrated resolution of symptoms with AC cell reduced to a 0.5+ level. Topical steroid tapering continued, with no recurrence noted at a six-month follow-up.; Reporter's Comments: Causality: Due to the spontaneous nature of the case, the events are considered related for reporting purposes. Related due to plausible temporal association (3 days after vaccination). Events ocular hyperaemia, eye pain, conjunctival hyperaemia photophobia, and blurred vision are more plausibly explained by Iridocyclitis. Of note, patient is HLA B27 positive which is considered as risk factor.
Medical History/Concurrent Conditions: High myopia